When

Saturday, November 06, 2021

7:45 PM - 9:45 PM CT

WheRE

New Orleans, LA

Hilton New Orleans Riverside Hotel
Grand Salon C (1st Floor)

2 Poydras Street
New Orleans, LA 70130

faculty

Reynold A. Panettieri, Jr, MD (Moderator)
Professor of Medicine, Robert Wood Johnson Medical School
Vice Chancellor, Translational Medicine and Science
Director, Rutgers Institute for Translational Medicine and Science
Emeritus Professor of Medicine, University of Pennsylvania
Child Health Institute of New Jersey
Rutgers, The State University of New Jersey
New Brunswick, New Jersey

Monica Kraft, MD
Professor of Medicine
Chair, Department of Medicine
The Robert and Irene Flinn Endowed Chair in Medicine
University of Arizona (UA) College of Medicine – Tucson
Deputy Director, UA Health Sciences Asthma and Airway Disease Research Center
Tucson, Arizona

Anju T. Peters, MD, MS
Professor of Medicine
Department of Allergy and Immunology
Department of Otolaryngology - Head and Neck Surgery
Director of Clinical Research
Division of Allergy and Immunology
Northwestern University Feinberg School of Medicine
Chicago, Illinois

Non-CME Corporate Forum

There is no registration fee for attending this Non-CME Corporate Forum; however, seating is limited. Preregistration does not guarantee seating. We recommend arriving at the meeting room early.  Dinner will be provided.

7:45 PM-8:15 PM CT: Dinner/Registration
8:15 PM-9:45 PM CT: Non-CME Corporate Forum

The Non-CME Corporate Forum content and views expressed therein do not necessarily reflect the views, policies or position of the American College of Allergy, Asthma & Immunology.

This activity is supported by AstraZeneca.

Target Audience

This activity addresses the needs of clinical immunologists, pulmonologists, and other physicians involved in the management of patients with severe asthma.

Program Description

Best practices within the management of severe asthma require the integration of evidence-based guidelines, the latest scientific information, and an accumulation of clinical experience—all which inform individualized treatment selection and chronic care decisions. To better mirror real-world practice, this Case-in-Point™ severe asthma program will utilize a case-based format to actively engage learners while emphasizing knowledge consolidation and translation. Within the context of these representative, challenging case studies, a multidisciplinary panel of expert faculty will review and discuss key topics including newer insights into type 2 (T2) high and T2 low asthma pathophysiology, the longitudinal assessment of severe disease, and the latest evidence and rationale for the implementation of available and emerging targeted therapies. 

Objectives

After completing this activity, the participant should be better able to:

  • Describe clinically relevant pathophysiologic processes in severe asthma, including implications for new targeted treatment options
  • Comprehensively assess patients with asthma for disease severity, lung function, and treatment responses
  • Discuss the mechanisms of action and clinical profiles of new and emerging targeted therapies for severe asthma
  • Individualized treatment regimens for patients with severe asthma based on symptoms, phenotypes, and patient preferences

Draft Agenda

7:45 PM-8:15 PM CT  Dinner/Registration
8:15 PM-8:20 PM CT  Welcome and Preactivity Polling
8:20 PM-8:50 PM CT  New Pathologic Insights Into Severe Asthma
8:50 PM-9:05 PM CT  Case #1: Managing Patients With T2 High Asthma
9:05 PM-9:10 PM CT  Case #1 Q&A Session
9:10 PM-9:25 PM CT  Case #2: Managing Patients With T2-Low Asthma
9:25 PM-9:30 PM CT  Case #2: Managing Patients With T2-Low Asthma
9:30 PM-9:45 PM CT  Postactivity Polling and Expert Q&A Session

Americans with Disabilities Act

Event staff will be glad to assist you with any special needs (ie, physical, dietary, etc). Please contact Christa Master prior to the live event at (727) 637-2945 or cmaster@integritasgrp.com.

Register Now

attend event
available resources
meeting slides
linked resources
Suggested Reading
Case-in-Point™

Cause for Alarm

New Avenues to the Management of Severe Asthma